Ask AI
New Targeted Combination for LGSOC
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer

Released: November 06, 2025

Activity

Progress
1
Course Completed

In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including:

  • Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selection
  • The recently approved targeted therapy combination regimen of avutometinib and defactinib for KRAS-mutant LGSOC (RAMP 201)
  • Promising future directions for patients with LGSOC based on ongoing studies such as RAMP 301 and CHAMELEON